CHICAGO--(BUSINESS WIRE)--Introgen Therapeutics, Inc. (NASDAQ: INGN) reported positive final data from a Phase 2 clinical trial of INGN 225 in patients with small cell lung cancer (SCLC) at the annual meeting of the American Society of Clinical Oncology in Chicago. In the 43 patients evaluable for survival following INGN 225 treatment, survival was superior to historical controls and five patients remain progression free from 378 to 894 days following vaccination with INGN 225. INGN 225 is an immunotherapy (vaccine) that utilizes an adenovector to deliver the p53 gene to a patient’s immune cells, stimulating an anti-tumor immune response.
